The document discusses a new skin care treatment called HD SkinStem GF complex from Hansderma. The GF complex contains important growth factors like EGF and FGF that are normally found in platelets and help accelerate wound healing and skin rejuvenation. These growth factors can be isolated from a patient's blood through platelet rich plasma extraction, but the GF complex provides them without blood draw. The complex contains growth factors, copper peptides, hyaluronic acid, and vitamins that stimulate collagen production, reduce inflammation, improve moisture and elasticity when applied using a microneedling device like Dermapen. Studies show microneedling delivers the complex into the dermis and increases skin thickness over time.

1. What skin care treatment is new at Aesthetic Laser Center?
The newest product I am using on patients is from Hansderma and it is called HD
SkinStem GF complex. This stands for SkinStem Growth Factor Complex.
What is in the GF complex?
It contains a couple of
important Growth Factors that
are present in one’s platelets
and are released when
procedures are performed on patients that cause skin injury such as micro-needling,
non-ablative lasers, LED, Radio frequency and chemical peels. These facilitate and
shorten the natural healing process and rejuvenate the skin. These growth
factors can be isolated in larger numbers by drawing a patient’s blood and isolating the
platelets in larger numbers which contain multiple growth factors. This is called PRP or
platelet rich plasma and I have been using this with the Dermapen to rejuvenate the skin
and treat a multitude of conditions. Unfortunately, not every patient wants to have their
blood drawn and the cost is $500 more that by using the Skin RE GF complex instead.
What is is the GF Complex?
Figure 1.
HD Skinstem GF Complex.

2. Two important growth factors included are
needled for skin repair and collagen remodeling.
These are EGF and FGF.
EGF stands for epidermal growth factor and
protein causes the growth of a wide range of
epidermal and epithelial cells. This directly
stimulates the proliferation of epidermal cells to
give a healthier and thicker skin surface. Not
only will you better looking skin, but the healing
process is accelerated.
FGF stands for fibroblast growth factor and this cytokine stimulates fibroblast synthesis
and creates new collagen and elastin in an orderly fashion that helps firm, smooth and
increase moisture content to the face. What one sees is improved texture , firmer skin
and less wrinkles.
The other products in the GF complex include Copper peptides which are anti-
inflammatory and and also stimulate skin remodeling. Hyaluronic Acid is also present
which improves the moisture of the skin and Vitamins C, B2-6 and B12, H and
Palmitoyl Peptide which improves elasticity, firmness and tone.
These are high quality, concentrated stable products manufactured in an FDA-
registered lab that meets their stringent quality control. They are very safe and are
100% similar to human proteins and are produced through a process called
recombinant DNA. This is the most common method of producing bioactive ingredients
in the cosmetic industry.
Figure 2.
Products in GF Complex.
Courtesy of HansDerma.

3. I like using the Dermapen which is the
world’s number one microneedling device with
unique AVONTM
technology, because it has
shown to delivery the active ingredients into the
dermis with the second pass of the pen. The
growth factors and vitamins help the recovery
process so there is minimal downtown.
Microneedling studies on rats have soon a 140%
increase in epidermis over controls when using skin
care creams or serums with Vit A and C. Human
studies performed by Aust et al. 1
showed an
increase skin thickness of 40% after 6 months
based on skin biopsies.
References:
Aust MC et al. Percutaneous
Collagen Induction
Therapy:
An
Figure 3. Production of FG by
Recombinant DNA technology.
Courtesy of HansDerma.
Before. After Dermapen GR treatment and fat
grafting to face.

4. alternative for Scars, Wrinkles, and Skin Laxity. Plas Reconstr Surg. 2008 April; 121(4)
1421-9.